Xolair (omalizumab) - Roche, Novartis
Hypersensitivity Reactions to Biologics: Advances in Diagnosis and Management. (PubMed, Curr Allergy Asthma Rep) - Sep 29, 2026 - "Recent approaches to rapid drug desensitization (RDD) include one-bag protocols, same-day desensitization, and omalizumab as an adjunct in selected patients. The approach to biologic hypersensitivity is increasingly guided by reaction phenotype, diagnostic evaluation, and individualized management." 
Journal • Review • Immunology • Inflammation • Oncology
http://www.ncbi.nlm.nih.gov/pubmed/42804013
 
Barbara C Yang
 
Sep 29, 2026
 
Prev Next